Zobrazeno 1 - 10
of 848
pro vyhledávání: '"P P Paolisso"'
Autor:
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, Ada Pesapane, Manuela Giovanna Basilicata, Puja Ghosh, Martina Franzese, Giovanni Tortorella, Armando Puocci, Maria Teresa Vietri, Annalisa Capuano, Giuseppe Paolisso, Michelangela Barbieri
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-13 (2024)
Abstract Tirzepatide is a new drug targeting glucagon-like peptide 1(GLP1) and gastric inhibitory polypeptide (GIP) receptors. This drug has demonstrated great potential in improving the clinical outcomes of patients with type 2 diabetes. It can lead
Externí odkaz:
https://doaj.org/article/4ca156c215ba43d686dcdf0858b6834f
Autor:
Fatemeh Taktaz, Lucia Scisciola, Rosaria Anna Fontanella, Ada Pesapane, Puja Ghosh, Martina Franzese, Giovanni Tortorella, Armando Puocci, Eduardo Sommella, Giuseppe Signoriello, Fabiola Olivieri, Michelangela Barbieri, Giuseppe Paolisso
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-15 (2024)
Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective antidiabetic drugs with potential cardiovascular benefits. Despite their well-established role in reducing the risk of major adverse cardiovascular events (MACE),
Externí odkaz:
https://doaj.org/article/84a24c088642420db1de6f8e5cb9fb78
Autor:
Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, Pier Francesco Rambaldi, Carlo Fumagalli, Ludovica Vittoria Marfella, Rosalba La Grotta, Chiara Frigé, Valeria Pellegrini, Davide D’Andrea, Arturo Cesaro, Paolo Calabrò, Carmine Pizzi, Roberto Antonicelli, Antonio Ceriello, Ciro Mauro, Giuseppe Paolisso
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-9 (2024)
Abstract Background Few studies explored the effect of the combination of glucose sodium-cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on the incidence of cardiovascular events in patients with type 2 di
Externí odkaz:
https://doaj.org/article/132b9c512d1a4999b08bdb1d8a813312
Autor:
Rosaria Anna Fontanella, Puja Ghosh, Ada Pesapane, Fatemeh Taktaz, Armando Puocci, Martina Franzese, Maria Federica Feliciano, Giovanni Tortorella, Lucia Scisciola, Eduardo Sommella, Concetta Ambrosino, Giuseppe Paolisso, Michelangela Barbieri
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background Several evidence demonstrated that glucagon-like peptide 1 receptor agonists (GLP1-RAs) reduce the risk of dementia in type 2 diabetes patients by improving memory, learning, and overcoming cognitive impairment. In this study, we
Externí odkaz:
https://doaj.org/article/3333edaddaa141dcabd6c2bdbfa2fe10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Celestino Sardu, Ludovica Vittoria Marfella, Valerio Giordano, Caterina Claudia Lepre, Giovanbattista D’Amico, Mario Volpicelli, Carla Contaldi, Raffaele Galiero, Alfredo Caturano, Flavia Casolaro, Ferdinando Carlo Sasso, Carlo Uran, Domenico Cozzolino, Maddalena Nicoletti, Giuseppe Signoriello, Giuseppe Paolisso, Raffaele Marfella
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundLeft bundle branch (LBB) pacing could achieve cardiac resynchronization therapy (CRT) in patients who cannot be resynchronized via the placement of the left ventricle (LV) lead into the coronary sinus. LBB pacing could improve cardiovascula
Externí odkaz:
https://doaj.org/article/dfe306813e7742218d7fd3ffbc5beebd
Autor:
Michelangela Barbieri, Paolo Chiodini, Piergiacomo Di Gennaro, Gaye Hafez, Sophie Liabeuf, Jolanta Malyszko, Laila-Yasmin Mani, Francesco Mattace-Raso, Marion Pepin, Norberto Perico, Mariadelina Simeoni, Carmine Zoccali, Giovanni Tortorella, Annalisa Capuano, Giuseppe Remuzzi, Giovambattista Capasso, Giuseppe Paolisso
Publikováno v:
Pharmacological Research, Vol 203, Iss , Pp 107146- (2024)
Patients with chronic kidney disease (CKD) often experience mild cognitive impairment and other neurocognitive disorders. Studies have shown that erythropoietin (EPO) and its receptor have neuroprotective effects in cell and animal models of nervous
Externí odkaz:
https://doaj.org/article/b20da874e82f40b4897517a2fb0f6b4c
Autor:
Davide Marchetti, Federica Buzzi, Riccardo Di Febo, Sara Modugno, Matteo Schillaci, Pasquale Paolisso, Marco Doldi, Eleonora Melotti, Angelo Ratti, Andrea Provera, Gianluca Guarnieri, Riccardo Terzi, Michele Gallazzi, Edoardo Conte, Daniele Andreini
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 16, p 4733 (2024)
Cardiac magnetic resonance (CMR) has acquired a pivotal role in modern cardiology. It represents the gold standard for biventricular volume and systolic function assessment. Moreover, CMR allows for non-invasive myocardial tissue evaluation, highligh
Externí odkaz:
https://doaj.org/article/b54883f1f3f940a5b6b6c33759f18ac1
Autor:
Pasquale Paolisso, MD, Anna Giulia Pavon, MD, Luca Bergamaschi, MD, Francesco Angeli, MD, Marta Belmonte, MD, Alberto Foà, MD, PhD, Lisa Canton, MD, Damiano Fedele, MD, Matteo Armillotta, MD, Angelo Sansonetti, MD, Francesca Bodega, MD, Sara Amicone, MD, Nicole Suma, MD, Emanuele Gallinoro, MD, PhD, Domenico Attinà, MD, Fabio Niro, MD, Luigi Lovato, MD, Paola Rucci, MD, Elisa Gherbesi, MD, Stefano Carugo, MD, Saima Mushtaq, MD, Andrea Baggiano, MD, Marco Guglielmo, MD, Edoardo Conte, MD, Daniele Andreini, Gianluca Pontone, MD, PhD, Carmine Pizzi, MD
Publikováno v:
Journal of Cardiovascular Magnetic Resonance, Vol 26, Iss , Pp 100691- (2024)
Externí odkaz:
https://doaj.org/article/7c88f2ea0f19427eb6e52e4ad97420b1
Autor:
Lucia Scisciola, Ugo Chianese, Vicky Caponigro, Manuela Giovanna Basilicata, Emanuela Salviati, Lucia Altucci, Pietro Campiglia, Giuseppe Paolisso, Michelangela Barbieri, Rosaria Benedetti, Eduardo Sommella
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-15 (2023)
Abstract Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment for type 2 diabetes mellitus (T2DM). Among them, empagliflozin (EMPA) has shown beneficial effects against heart failure. Because cardiovas
Externí odkaz:
https://doaj.org/article/f9085a4fe01747819d1ef129d4319709